METHOD FOR PREDICTION OF RISK OF PROGRESSION OF METASTATIC COLORECTAL CANCER AFTER ANTI-EGFR THERAPY Russian patent published in 2024 - IPC A61B5/153 G01N33/49 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology. At the prehospital stage during initial presentation, before the beginning of the drug therapy, the peripheral blood is sampled. Blood serum is recovered with subsequent aliquotation and determination of concentration of cytokines IFNg, IL4, MIP1 by enzyme immunoassay. Risk of progression of metastatic colorectal cancer after targeted anti-EGFR therapy is calculated by formula K=expz/(1+expz), where K is the probability of disease progression from 0 to 1; z is regression coefficient; z = 6.67-1.46*X1-0.98*X2-0.054*X3; X1 is concentration of cytokine IFNg in blood serum, X2 is concentration of cytokine IL4 in blood serum, X3 is concentration of cytokine MIP1a in blood serum, 6.67, -1.46, -0.98, -0.054 are coefficients. If K is less than 0.16, the risk of progression is predicted to be low. If K is equal to or greater than 0.16, the risk of progression is high.

EFFECT: method enables predicting the effectiveness of the anti-tumour anti-EGFR therapy of metastatic colorectal cancer.

1 cl, 3 dwg, 3 ex